@neurology_live : Now enrolling patients across the US and Europe, the phase 2b ExTINGUISH trial is a multicenter study evaluating 3500-mg inebilizumab for moderate-to-severe #NMDAR encephalitis. Led by @StaceyLClardy, MD, PhD, FAAN, of @UfUNeurology, the newly published trial design outlines a • TwiCopy

NeurologyLive®

@neurology_live

+ Follow

Delivering healthcare professionals treating neurological diseases quality and relevant information to help achieve the best patient care possible. #MindMoments

ID: 1016356467073585152

linkhttp://neurologylive.com calendar_today09-07-2018 16:20:39

38,38K Tweet

9,9K Takipçi

802 Takip Edilen

NeurologyLive®

@neurology_live

2 months ago

Now enrolling patients across the US and Europe, the phase 2b ExTINGUISH trial is a multicenter study evaluating 300-mg inebilizumab for moderate-to-severe #NMDAR encephalitis. Led by Stacey Clardy MD PhD, MD, PhD, FAAN, of @UfUNeurology, the newly published trial design outlines a

thumb_up_off_alt8

chat_bubble_outline1

repeat6

shareShare